Evidence map›Paper›PMID 40849750›Full record

SynthesisCurrent medicinal chemistry2026

Romosozumab's Effect on Bone Mineral Density in Patients with Osteoporosis: A Systematic Review and Meta-Analysis.

Hooman Yahyazadeh, Tahereh Farkhondeh, Abolfazl Bagherifard, Karo Khosravi, Reza Ahmadi, Hamed Aramjoo, Babak Roshanravan, Saeed Samarghandian

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hooman YahyazadehDepartment of Orthopedic Surgery, Farhikhtegan Hospital, Faculty of Medicine, Tehran Medical Sciences Islamic Azad University, Tehran, Iran.
Tahereh FarkhondehGeriatric Health Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Abolfazl BagherifardDepartment of Orthopedics, Shafa Yahyaeian Orthopedic Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran.
Karo KhosraviDepartment of Orthopedics, Bone and Joint Reconstruction Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran.
Reza AhmadiDepartment of Orthopedics, Shafa Yahyaeian Orthopedic Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran.
Hamed AramjooGeriatric Health Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Babak RoshanravanGeriatric Health Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Saeed SamarghandianDepartment of Medical Physiology, School of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOne of the most effective osteoanabolic drugs for treating osteoporosis is romosozumab, which was developed as a consequence of growing knowledge of the Wnt signaling system. This review explored how romosozumab affects the bone mineral density (BMD) in osteoporotic patients.

methodsUp until January 2024, PubMed, Web of Science, and Scopus were reviewed for any randomized controlled trials (RCTs) evaluating the impact of osteoporotic treatment with romosozumab on BMD changes and bone metabolism markers in primary osteoporosis patients. Pooled Hedges' g indices, which were consistently used across all included studies to measure standardized mean differences, were computed along with their corresponding 95% confidence intervals using either a random-effects or fixed-effects model.

resultsOut of the 1855 papers, 24 RCTs met the inclusion criteria. Patients with osteoporosis who received romosozumab for a period of time demonstrated an augmentation in their lumbar spine BMD. The study findings indicated that the total hip and femoral neck BMD demonstrated significant enhancement in 22 (out of 23) and 19 (out of 21) studies, respectively.

conclusionIn patients with osteoporosis, romosozumab could markedly increase the total hip, lumbar spine, and femoral neck BMD. This finding could be verified by measuring bone turnover indicators such as PINP, TRACP-5b, and CTX.

Indexed as

Antibodies, MonoclonalBone DensityBone Density Conservation AgentsOsteoporosisHumansAntibodies, MonoclonalBone Density Conservation AgentsromosozumabbisphosphonatesBMDCTXPINPRomosozumabTRACP-5b

Identifiers

PMID40849750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.